Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HARRY EARL STUDDARD

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1144217837
CMS profile
6941
Location
MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,887.76

105 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,693.36 100
Education $174.40 4
Gift $20.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HARRY EARL STUDDARD

NPI 1144217837 · CMS profile ID 6941

Allopathic & Osteopathic Physicians / Internal Medicine

MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144217837?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HARRY EARL STUDDARD, NPI 1144217837, CMS profile ID 6941. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144217837?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). HARRY EARL STUDDARD, NPI 1144217837, CMS profile ID 6941. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144217837?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
HARRY EARL STUDDARD, NPI 1144217837, CMS profile ID 6941, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1144217837?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

105 matching records · $1,887.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 105 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–105 of 105.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amarin Pharma Inc. $15.1801/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815386931 CMS
Eisai Inc. $19.3201/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817808353 CMS
Antares Pharma, Inc. $18.7201/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827485085 CMS
AbbVie Inc. $16.5701/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796106561 CMS
Esperion Therapeutics, Inc. $13.5501/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838416051 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,001.50 67
PY2020 $887.77 54
PY2021 $1,887.76 105
PY2022 $1,119.13 59
PY2023 $1,114.59 62
PY2024 $1,019.74 58
PY2025 $596.16 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,466,022.53 240
PY2024 Recipient $26,171.00 2
PY2024 Principal investigator $2,306,086.10 175
PY2023 Recipient $620.01 1
PY2023 Principal investigator $1,267,298.09 431
PY2022 Principal investigator $2,872,636.12 235
PY2021 Principal investigator $1,852,676.67 133
PY2020 Principal investigator $1,424,628.27 352
PY2019 Principal investigator $1,686,079.54 965

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

240 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $2,180.00 12/31/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight or Obesity No dispute reported 06/30/2026 1185555437
Principal investigator 1 Currax Pharmaceuticals LLC $897.50 12/24/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715516
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228722756
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725248
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725530
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725700
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228730855
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228730858
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228732839
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228733394
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228733401
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228733647
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228733651
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228733901
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228733906
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228734020
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228734811
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228734815
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228734820
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228735031
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228735161
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228737003
Principal investigator 1 PFIZER INC. $1,170.00 12/18/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228729147
Principal investigator 1 PFIZER INC. $1,170.00 12/18/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228729152
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 12/17/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725584
Principal investigator 1 Boehringer Ingelheim International GmbH $13.92 12/17/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725586
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,777.32 12/15/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798889
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 12/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725562
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725564
Principal investigator 1 Boehringer Ingelheim International GmbH $49.88 12/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725566
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725568
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725570
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725572
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725574
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725576
Principal investigator 1 SANOFI PASTEUR INC. $7,375.20 11/21/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226107427
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 11/19/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725578
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 11/19/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725580
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 11/19/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725582
Principal investigator 1 ViiV Healthcare Company $1,000.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A PHASE 1 SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINETI No dispute reported 06/30/2026 1190317715
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,588.00 11/12/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185555439
Principal investigator 1 Bavarian Nordic A/S $3,524.88 11/12/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214738
Principal investigator 1 ViiV Healthcare Company $38,803.99 11/07/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A PHASE 1 SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINETI No dispute reported 06/30/2026 1190317719
Principal investigator 1 Janssen Research & Development, LLC $287.00 11/03/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older No dispute reported 06/30/2026 1175400696
Principal investigator 1 SANOFI PASTEUR INC. $650.00 11/03/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226107333
Principal investigator 1 ViiV Healthcare Company $12,318.27 11/03/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A PHASE 1 SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINETI No dispute reported 06/30/2026 1190314995
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725550
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725552
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725554
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725556
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725558
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725560
Principal investigator 1 PFIZER INC. $8,446.00 11/01/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228739327
Principal investigator 1 SANOFI PASTEUR INC. $436.80 10/30/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226107643
Principal investigator 1 SANOFI PASTEUR INC. $650.00 10/30/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226107648
Principal investigator 1 SANOFI PASTEUR INC. $1,906.00 10/30/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226107654
Principal investigator 1 SANOFI PASTEUR INC. $2,500.00 10/30/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226107662
Principal investigator 1 SANOFI PASTEUR INC. $2,600.00 10/30/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226107668
Principal investigator 1 Bavarian Nordic A/S $2,926.00 10/29/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214752
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,130.30 10/29/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798597
Principal investigator 1 ViiV Healthcare Company $13,500.00 10/29/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A PHASE 1 SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINETI No dispute reported 06/30/2026 1190317717
Principal investigator 1 Eli Lilly and Company $22,794.96 10/28/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187877843
Principal investigator 1 Currax Pharmaceuticals LLC $1,200.00 10/23/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715504
Principal investigator 1 SANOFI PASTEUR INC. $22,125.60 10/23/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226107546
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $105.00 10/22/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798591
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $279.00 10/22/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798593
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $315.00 10/22/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798595
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $450.00 10/22/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798885
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $465.00 10/22/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798887
Principal investigator 1 SANOFI PASTEUR INC. $14,567.00 10/17/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226107377
Principal investigator 1 Janssen Research & Development, LLC $750.00 10/16/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older No dispute reported 06/30/2026 1175400710
Principal investigator 1 Janssen Research & Development, LLC $2,733.00 10/16/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older No dispute reported 06/30/2026 1175400731
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 10/16/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older No dispute reported 06/30/2026 1175400741
Principal investigator 1 AstraZeneca Pharmaceuticals LP $145.38 10/15/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185555433
Principal investigator 1 Currax Pharmaceuticals LLC $1,542.25 10/14/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715492
Principal investigator 1 Currax Pharmaceuticals LLC $1,142.40 10/14/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715496
Principal investigator 1 Currax Pharmaceuticals LLC $1,498.00 10/14/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715498
Principal investigator 1 Currax Pharmaceuticals LLC $1,142.40 10/14/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715500
Principal investigator 1 Currax Pharmaceuticals LLC $1,142.40 10/14/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715502
Principal investigator 1 PFIZER INC. $1,715.28 10/08/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228714164
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $450.00 10/06/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798583
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $105.00 10/06/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798585
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 10/06/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798587
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,350.00 10/06/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798589
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $795.00 10/06/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798875
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $450.00 10/06/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798877
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $105.00 10/06/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798879
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $450.00 10/06/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798881
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $594.00 10/06/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798883
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,000.00 10/03/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798599
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725538
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725540
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725542
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725544
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725546
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725548
Principal investigator 1 Bavarian Nordic A/S $2,520.37 09/26/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214720
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 09/24/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725530
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 09/24/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725532
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 09/24/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725534
Principal investigator 1 Boehringer Ingelheim International GmbH $17.40 09/24/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725536
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/22/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808018
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,910.96 09/18/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798581
Principal investigator 1 PFIZER INC. $571.76 09/03/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228743293
Principal investigator 1 PFIZER INC. $5,866.42 09/03/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228750965
Principal investigator 1 ViiV Healthcare Company $14,094.88 09/03/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH MOBILE
A PHASE 1 SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINETI No dispute reported 06/30/2026 1190317721
Principal investigator 1 Bavarian Nordic A/S $19,335.94 09/02/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214708
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725496
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725498
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725500
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725502
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725504
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725522
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 09/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725524
Principal investigator 1 Boehringer Ingelheim International GmbH $1,058.50 08/26/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725526
Principal investigator 1 Boehringer Ingelheim International GmbH $15.66 08/26/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725528
Principal investigator 1 ViiV Healthcare Company $25,211.88 08/22/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH MOBILE
A PHASE 1 SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINETI No dispute reported 06/30/2026 1190317723
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,986.06 08/06/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798579
Principal investigator 1 PFIZER INC. $5,225.64 08/05/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228768161
Principal investigator 1 Bavarian Nordic A/S $371.80 08/01/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214698
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725478
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725480
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725482
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725484
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725486
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725488
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725490
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725492
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725494
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 08/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725516
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725520
Principal investigator 1 PFIZER INC. $3,791.20 07/17/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228785486
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725506
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725508
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725510
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725512
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725514
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725518
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,218.90 06/26/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798577
Principal investigator 1 PFIZER INC. $7,369.60 06/26/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228793554
Principal investigator 1 Bavarian Nordic A/S $743.60 06/25/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214664
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 06/24/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725472
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 06/24/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725474
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 06/24/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725476
Principal investigator 1 Currax Pharmaceuticals LLC $2,677.70 06/24/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715482
Principal investigator 1 SANOFI PASTEUR INC. $3,801.00 06/13/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research,llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226113116
Principal investigator 1 GlaxoSmithKline, LLC. $5,735.64 06/11/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1192109603
Principal investigator 1 Bavarian Nordic A/S $5,261.63 06/04/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214656
Principal investigator 1 Bavarian Nordic A/S $680.34 06/02/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214692
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725452
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725454
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725456
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725458
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725460
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725462
Principal investigator 1 PFIZER INC. $15,852.20 05/29/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228772902
Principal investigator 1 Currax Pharmaceuticals LLC $2,326.95 05/28/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715474
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 05/27/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725468
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 05/27/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725470
Principal investigator 1 SANOFI PASTEUR INC. $34,971.16 05/16/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research,llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226113784
Principal investigator 1 ViiV Healthcare Company $80,282.72 05/15/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A PHASE 1 SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINETI No dispute reported 06/30/2026 1190317725
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,049.58 05/09/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798575
Principal investigator 1 PFIZER INC. $14,100.00 05/06/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228773790
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725438
Principal investigator 1 Boehringer Ingelheim International GmbH $64.50 05/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725440
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725442
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725444
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725446
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725448
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725450
Principal investigator 1 SANOFI PASTEUR INC. $199,767.64 04/28/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research,llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226113518
Principal investigator 1 Bavarian Nordic A/S $15,452.23 04/25/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214654
Principal investigator 1 Currax Pharmaceuticals LLC $3,771.20 04/24/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715466
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 04/23/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725464
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 04/23/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725466
Principal investigator 1 PFIZER INC. $3,448.16 04/15/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228707552
Principal investigator 1 PFIZER INC. $3,448.16 04/15/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228759866
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,778.48 04/11/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798573
Principal investigator 1 PFIZER INC. $7,327.34 04/08/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228707554
Principal investigator 1 PFIZER INC. $7,327.34 04/08/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228761088
Principal investigator 1 PFIZER INC. $15,839.67 04/08/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228781391
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725426
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725428
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725430
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725432
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725434
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725436
Principal investigator 1 Currax Pharmaceuticals LLC $5,340.60 03/27/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715442
Principal investigator 1 Bavarian Nordic A/S $9,439.20 03/26/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214612
Principal investigator 1 Bavarian Nordic A/S $50,409.27 03/21/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214608
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,972.44 03/17/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798571
Principal investigator 1 PFIZER INC. $1,279.80 03/17/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC Mobile
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228713990
Principal investigator 1 PFIZER INC. $677.05 03/17/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228774149
Principal investigator 1 PFIZER INC. $793.65 03/17/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228774153
Principal investigator 1 PFIZER INC. $793.65 03/17/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228775916
Principal investigator 1 PFIZER INC. $677.05 03/17/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228786397
Principal investigator 1 Bavarian Nordic A/S $49,018.75 03/03/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214596
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725406
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725408
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725410
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725412
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725414
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725416
Principal investigator 1 Currax Pharmaceuticals LLC $1,142.40 02/27/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715410
Principal investigator 1 Amgen Inc. $49,367.45 02/25/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) No dispute reported 06/30/2026 1246639027
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 02/25/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725418
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 02/25/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725420
Principal investigator 1 Eli Lilly and Company $4,164.97 02/25/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187874491
Principal investigator 1 Currax Pharmaceuticals LLC $4,329.95 02/20/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715428
Principal investigator 1 PFIZER INC. $50,805.60 02/08/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228757604
Principal investigator 1 Currax Pharmaceuticals LLC $571.20 02/06/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715406
Principal investigator 1 Currax Pharmaceuticals LLC $856.80 02/06/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715408
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725394
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725396
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725398
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725400
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725402
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725404
Principal investigator 1 Eli Lilly and Company $150.00 01/31/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187880539
Principal investigator 1 Currax Pharmaceuticals LLC $1,100.00 01/30/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715414
Principal investigator 1 Currax Pharmaceuticals LLC $1,444.25 01/30/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715422
Principal investigator 1 Eli Lilly and Company $28,660.00 01/28/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187872545
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,296.28 01/27/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798569
Principal investigator 1 Amgen Inc. $277,598.08 01/26/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight No dispute reported 06/30/2026 1246639043
Principal investigator 1 PFIZER INC. $250.00 01/22/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228799104
Principal investigator 1 Eli Lilly and Company $92,479.00 01/21/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187876279
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,679.32 01/17/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798567
Principal investigator 1 Bavarian Nordic A/S $1,311.00 01/15/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214632
Principal investigator 1 Bavarian Nordic A/S $262.20 01/15/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214634
Principal investigator 1 Bavarian Nordic A/S $262.20 01/15/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214758
Principal investigator 1 PFIZER INC. $2,088.52 01/15/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228719969
Principal investigator 1 PFIZER INC. $5,000.00 01/15/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228801494
Principal investigator 1 AstraZeneca UK Limited $47,361.90 01/13/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185555435
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725384
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725386
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725388
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725390
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725392
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 01/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725422
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Amr Coastal Clinical Research-Mobile
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220725424